Rezolute’s Ersodetug Shows Promise in Phase 3 Trials for CHI, Reinforcing Buy Rating and $12 Price Target

JonesTrading analyst Catherine Novack has reiterated their bullish stance on RZLT stock, giving a Buy rating yesterday.

Catherine Novack’s rating is based on several promising developments for Rezolute’s lead drug candidate, ersodetug, which is progressing well in its clinical trials. The company recently reported its F3Q25 earnings, and while there were no significant updates regarding financial catalysts or cash runway, the focus remains on the pivotal data expected in December 2025 for congenital hyperinsulinism (CHI). In previous trials, high doses of ersodetug demonstrated a significant reduction in hypoglycemia events, which is a primary endpoint for the ongoing Phase 3 trials.
Additionally, the market opportunity for CHI, although small, is significant, with potential label expansion into tumor-induced hyperinsulinism that could nearly double the market size. The ongoing Phase 3 trial has met expectations, with interim analysis supporting its continuation without increasing the sample size. This progress, along with the activation of US sites for patient enrollment, strengthens the case for a successful NDA submission for US approval, reinforcing the Buy rating and the $12 price target.

In another report released yesterday, Wedbush also reiterated a Buy rating on the stock with a $12.00 price target.

Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RZLT in relation to earlier this year.